A Validated, Stability‐Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance
Biomedical Chromatography · 2025-07 · 39 (7)
DOI: 10.1002/bmc.70118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 29.05.2025. Verfasst von Lixiang Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen JXBio Pharmaceutical Co., Ltd, Shenzhen, China. Hauptthemen laut MEDLINE: Liraglutide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Program.
Abstract (Originalsprache)
Liraglutide, an analog of glucagon‐like peptide‐1, is a treatment for the management of type 2 diabetes mellitus and obesity. In this study, we developed and validated a straightforward, sensitive, and reproducible gradient reverse‐phase high‐performance liquid chromatographic method for the separation and quantification of related substances in liraglutide drug substance. A C8 column was employed as the chromatographic column, with a mobile phase comprising phosphate buffer solution and acetonitrile. Under optimized chromatographic conditions, five specific impurities within liraglutide could be efficiently separated simultaneously. The resolution between main peak and each impurity was greater than 1.0, and the tailing factor of the main peak was less than 1.0. This method exhibited high sensitivity and enabled quantitative determination of both liraglutide and each impurity, thereby effectively ensuring the quality control of liraglutide products. The developed method is validated in accordance with the guidelines set by the International Conference on Harmonization regarding specificity, linearity, limit of detection, limit of quantification, accuracy, precision, and robustness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen JXBio Pharmaceutical Co., Ltd, Shenzhen, China.
- Shenzhen JYMed Technology Co., Ltd, Shenzhen, China.
ORCID-Profile: Lixiang Zhang
Förderung
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Zhang, L., Li, X., Zhang, J., Wang, X., & Fu, Y. (2025). A Validated, Stability‐Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance. Biomedical Chromatography, 39(7). https://doi.org/10.1002/bmc.70118
Vancouver
Zhang L, Li X, Zhang J, Wang X, Fu Y. A Validated, Stability‐Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance. Biomedical Chromatography. 2025;39(7). doi:10.1002/bmc.70118
BibTeX
@article{Zhang2025,
author = {Zhang, Lixiang and Li, Xinyu and Zhang, Jiansong and Wang, Xiao and Fu, Yuqing},
title = {A Validated, Stability‐Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance},
journal = {Biomedical Chromatography},
year = {2025},
volume = {39},
number = {7},
doi = {10.1002/bmc.70118}
}
EUVIMED